Your browser doesn't support javascript.
loading
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.
Dareng, Eileen O; Coetzee, Simon G; Tyrer, Jonathan P; Peng, Pei-Chen; Rosenow, Will; Chen, Stephanie; Davis, Brian D; Dezem, Felipe Segato; Seo, Ji-Heui; Nameki, Robbin; Reyes, Alberto L; Aben, Katja K H; Anton-Culver, Hoda; Antonenkova, Natalia N; Aravantinos, Gerasimos; Bandera, Elisa V; Beane Freeman, Laura E; Beckmann, Matthias W; Beeghly-Fadiel, Alicia; Benitez, Javier; Bernardini, Marcus Q; Bjorge, Line; Black, Amanda; Bogdanova, Natalia V; Bolton, Kelly L; Brenton, James D; Budzilowska, Agnieszka; Butzow, Ralf; Cai, Hui; Campbell, Ian; Cannioto, Rikki; Chang-Claude, Jenny; Chanock, Stephen J; Chen, Kexin; Chenevix-Trench, Georgia; Chiew, Yoke-Eng; Cook, Linda S; DeFazio, Anna; Dennis, Joe; Doherty, Jennifer A; Dörk, Thilo; du Bois, Andreas; Dürst, Matthias; Eccles, Diana M; Ene, Gabrielle; Fasching, Peter A; Flanagan, James M; Fortner, Renée T; Fostira, Florentia; Gentry-Maharaj, Aleksandra.
  • Dareng EO; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Coetzee SG; Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Tyrer JP; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Peng PC; Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Rosenow W; 3Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
  • Chen S; Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Applied Genomics, Computation and Translational Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Davis BD; Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Applied Genomics, Computation and Translational Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Dezem FS; Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Nameki R; Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Reyes AL; Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Aben KKH; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
  • Anton-Culver H; Department of Medicine, Genetic Epidemiology Research Institute, University of California, Irvine, Irvine, CA, USA.
  • Antonenkova NN; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
  • Aravantinos G; Agii Anargiri' Cancer Hospital, Athens, Greece.
  • Bandera EV; Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Beane Freeman LE; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
  • Beckmann MW; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  • Beeghly-Fadiel A; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Benitez J; Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
  • Bernardini MQ; Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, ON, Canada.
  • Bjorge L; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Black A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Bogdanova NV; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus; Department of Radiation Oncology, Hannover Medical School, Hannover, Germany; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Bolton KL; Division of Biology and Biomedical Sciences, Washington University, St. Louis, MO, USA.
  • Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Budzilowska A; Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Butzow R; Department of Pathology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Cai H; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Campbell I; Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Center, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Cannioto R; Cancer Pathology & Prevention, Division of Cancer Prevention and Population Sciences, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Chang-Claude J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Chanock SJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
  • Chen K; Department of Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Chenevix-Trench G; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Chiew YE; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia.
  • Cook LS; Epidemiology, School of Public Health, University of Colorado, Aurora, CO, USA; Community Health Sciences, University of Calgary, Calgary, AB, Canada.
  • DeFazio A; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia; The Daffodil Centre, a joint venture with Cancer Council NSW, The University of Sydney, Sydney, NSW, Australia.
  • Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Doherty JA; Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
  • Dörk T; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • du Bois A; Department of Gynecology and Gynecological Oncology; HSK, Dr. Horst-Schmidt Klinik, Wiesbaden, Wiesbaden, Germany; Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen-Mitte (KEM), Essen, Germany.
  • Dürst M; Department of Gynaecology, Jena University Hospital - Friedrich Schiller University, Jena, Germany.
  • Eccles DM; Faculty of Medicine, University of Southampton, Southampton, UK.
  • Ene G; Division of Gynecologic Oncology, University Health Network, Princess Margaret Hospital, Toronto, ON, Canada.
  • Fasching PA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  • Flanagan JM; Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Fortner RT; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Fostira F; Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece.
  • Gentry-Maharaj A; MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
Am J Hum Genet ; 111(6): 1061-1083, 2024 Jun 06.
Article en En | MEDLINE | ID: mdl-38723632
ABSTRACT
To identify credible causal risk variants (CCVs) associated with different histotypes of epithelial ovarian cancer (EOC), we performed genome-wide association analysis for 470,825 genotyped and 10,163,797 imputed SNPs in 25,981 EOC cases and 105,724 controls of European origin. We identified five histotype-specific EOC risk regions (p value <5 × 10-8) and confirmed previously reported associations for 27 risk regions. Conditional analyses identified an additional 11 signals independent of the primary signal at six risk regions (p value <10-5). Fine mapping identified 4,008 CCVs in these regions, of which 1,452 CCVs were located in ovarian cancer-related chromatin marks with significant enrichment in active enhancers, active promoters, and active regions for CCVs from each EOC histotype. Transcriptome-wide association and colocalization analyses across histotypes using tissue-specific and cross-tissue datasets identified 86 candidate susceptibility genes in known EOC risk regions and 32 genes in 23 additional genomic regions that may represent novel EOC risk loci (false discovery rate <0.05). Finally, by integrating genome-wide HiChIP interactome analysis with transcriptome-wide association study (TWAS), variant effect predictor, transcription factor ChIP-seq, and motifbreakR data, we identified candidate gene-CCV interactions at each locus. This included risk loci where TWAS identified one or more candidate susceptibility genes (e.g., HOXD-AS2, HOXD8, and HOXD3 at 2q31) and other loci where no candidate gene was identified (e.g., MYC and PVT1 at 8q24) by TWAS. In summary, this study describes a functional framework and provides a greater understanding of the biological significance of risk alleles and candidate gene targets at EOC susceptibility loci identified by a genome-wide association study.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Estudio de Asociación del Genoma Completo Límite: Female / Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Estudio de Asociación del Genoma Completo Límite: Female / Humans Idioma: En Año: 2024 Tipo del documento: Article